IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i7d10.1007_s40264-021-01073-z.html
   My bibliography  Save this article

Signal Detection in EUROmediCAT: Identification and Evaluation of Medication–Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference

Author

Listed:
  • Alana Cavadino

    (the University of Auckland)

  • Lovisa Sandberg

    (Uppsala Monitoring Centre)

  • Inger Öhman

    (Uppsala Monitoring Centre)

  • Tomas Bergvall

    (Uppsala Monitoring Centre)

  • Kristina Star

    (Uppsala Monitoring Centre
    Uppsala University)

  • Helen Dolk

    (Ulster University)

  • Maria Loane

    (Ulster University)

  • Marie-Claude Addor

    (University Hospital Center CHUV)

  • Ingeborg Barisic

    (Medical School University of Zagreb)

  • Clara Cavero-Carbonell

    (Foundation for the Promotion of Health and Biomedical Research in the Valencian Region)

  • Ester Garne

    (Hospital Lillebaelt)

  • Miriam Gatt

    (Malta Congenital Anomalies Registry, Directorate for Health Information and Research)

  • Babak Khoshnood

    (Paris Registry of Congenital Malformations, Obstetrical, Perinatal and Paediatric Epidemiology Research Team, Centre for Biostatistics and Epidemiology, INSERM, UMR 1153)

  • Kari Klungsøyr

    (University of Bergen)

  • Anna Latos-Bielenska

    (Poznan University of Medical Sciences)

  • Nathalie Lelong

    (Paris Registry of Congenital Malformations, Obstetrical, Perinatal and Paediatric Epidemiology Research Team, Centre for Biostatistics and Epidemiology, INSERM, UMR 1153)

  • Reneé Lutke

    (University of Groningen, University Medical Centre Groningen)

  • Anna Materna-Kiryluk

    (Poznan University of Medical Sciences)

  • Vera Nelen

    (PIH)

  • Amanda Nevill

    (University of Ferrara)

  • Mary O’Mahony

    (Health Service Executive-South)

  • Olatz Mokoroa

    (Public Health Division of Gipuzkoa)

  • Anna Pierini

    (Institute of Clinical Physiology, National Research Council/Fondazione Toscana Gabriele Monasterio)

  • Hanitra Randrianaivo

    (Unit of congenital malformations, REMACOR- Medical School University of La Réunion St Pierre)

  • Anke Rissmann

    (Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke-University)

  • David Tucker

    (Public Health Wales Knowledge Directorate, Level 3, West Wing Block, Singleton Hospital)

  • Awi Wiesel

    (Birth Registry Mainz Model, University Medical Center of Mainz)

  • Lyubov Yevtushok

    (OMNI-Net Ukraine Birth Defects Program and Rivne Regional Medical Diagnostic Center)

  • Joan K Morris

    (Population Health Research Institute, St George’s, University of London)

Abstract

Introduction Knowledge on the safety of medication use during pregnancy is often sparse. Pregnant women are generally excluded from clinical trials, and there is a dependence on post-marketing surveillance to identify teratogenic medications. Aims This study aimed to identify signals of potentially teratogenic medications using EUROmediCAT registry data on medication exposure in pregnancies with a congenital anomaly, and to investigate the use of VigiBase reports of adverse events of medications in the evaluation of these signals. Methods Signals of medication–congenital anomaly associations were identified in EUROmediCAT (21,636 congenital anomaly cases with 32,619 medication exposures), then investigated in a subset of VigiBase (45,749 cases and 165,121 exposures), by reviewing statistical reporting patterns and VigiBase case reports. Evidence from the literature and quantitative and qualitative aspects of both datasets were considered before recommending signals as warranting further independent investigation. Results EUROmediCAT analysis identified 49 signals of medication–congenital anomaly associations. Incorporating investigation in VigiBase and the literature, these were categorised as follows: four non-specific medications; 11 likely due to maternal disease; 11 well-established teratogens; two reviewed in previous EUROmediCAT studies with limited additional evidence; and 13 with insufficient basis for recommending follow-up. Independent investigations are recommended for eight signals: pregnen (4) derivatives with limb reduction; nitrofuran derivatives with cleft palate and patent ductus arteriosus; salicylic acid and derivatives with atresia or stenosis of other parts of the small intestine and tetralogy of Fallot; carbamazepine with atrioventricular septal defect and severe congenital heart defect; and selective beta-2-adrenoreceptor agonists with posterior urethral valve and/or prune belly. Conclusion EUROmediCAT data should continue to be used for signal detection, accompanied by information from VigiBase and review of the existing literature to prioritise signals for further independent evaluation.

Suggested Citation

  • Alana Cavadino & Lovisa Sandberg & Inger Öhman & Tomas Bergvall & Kristina Star & Helen Dolk & Maria Loane & Marie-Claude Addor & Ingeborg Barisic & Clara Cavero-Carbonell & Ester Garne & Miriam Gatt , 2021. "Signal Detection in EUROmediCAT: Identification and Evaluation of Medication–Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference," Drug Safety, Springer, vol. 44(7), pages 765-785, July.
  • Handle: RePEc:spr:drugsa:v:44:y:2021:i:7:d:10.1007_s40264-021-01073-z
    DOI: 10.1007/s40264-021-01073-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-021-01073-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-021-01073-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. R. A. Charlton & A. McGrogan & J. Snowball & L. M. Yates & A. Wood & J. Clayton-Smith & W. H. Smithson & J. L. Richardson & N. McHugh & S. H. L. Thomas & G. A. Baker & R. Bromley, 2017. "Sensitivity of the UK Clinical Practice Research Datalink to Detect Neurodevelopmental Effects of Medicine Exposure in Utero: Comparative Analysis of an Antiepileptic Drug-Exposed Cohort," Drug Safety, Springer, vol. 40(5), pages 387-397, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Laure Sillis & Veerle Foulon & Jan Y. Verbakel & Michael Ceulemans, 2022. "Experiences and Perspectives of Marketing Authorisation Holders towards Medication Safety Monitoring during Pregnancy: A Pan-European Qualitative Analysis," IJERPH, MDPI, vol. 19(7), pages 1-13, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jonathan L. Richardson & Alan Moore & Rebecca L. Bromley & Michael Stellfeld & Yvonne Geissbühler & Matthew Bluett-Duncan & Ursula Winterfeld & Guillaume Favre & Amalia Alexe & Alison M. Oliver & Yrea, 2023. "Core Data Elements for Pregnancy Pharmacovigilance Studies Using Primary Source Data Collection Methods: Recommendations from the IMI ConcePTION Project," Drug Safety, Springer, vol. 46(5), pages 479-491, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:7:d:10.1007_s40264-021-01073-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.